Showing 231-240 of 9294 results for "".
Rosacea: Choosing Among the Topical and Systemic Therapeutic Options
https://practicaldermatology.com/topics/general-topics/rosacea-choosing-among-the-topical-and-systemic-therapeutic-options/21706/As the field of therapies available for rosacea has expanded, clinicians must weigh the topical and oral treatment options on a case-by-case basisAdvances in the Treatment of Reticular Erythematous Mucinosis
https://practicaldermatology.com/youngmd-connect/resident-resource-center/advances-in-the-treatment-of-reticular-erythematous-mucinosis/23491/Considering nicotinamide’s anti-inflammatory properties for inflammatory dermatological conditions to avoid steroid and antibiotic overuse.The Microbiome in Acne: Where are We Now?
https://practicaldermatology.com/topics/acne-rosacea/the-microbiome-in-acne-where-are-we-now/23731/As research reveals connections of the microbiome to skin disease, clinicians may discover new approaches to managing the disease.Study Highlights Top-Rated Dermatology Education Apps
https://practicaldermatology.com/topics/practice-management/study-highlights-top-rated-dermatology-education-apps/23565/Researchers rated apps based on four key features.GLP-1 Receptor Agonists and the Aesthetic Patient: Considerations for the Dermatologist
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1-receptor-agonists-and-the-aesthetic-patient/48900/The impact of glucagon-like peptide-1 agonists (GLP-1), such as semaglutide, tirzepatide and liraglutide, has transformed the healthcare industry and, in particular, aesthetic dermatology. The most common intended use of these medications, namely diabetes management and weight loss, can lead to a muComorbidities in Atopic Dermatitis
https://practicaldermatology.com/issues/october-2025/comorbidities-in-atopic-dermatitis/39756/In this article, as part of a series on comorbidities associated with immune-mediated skin diseases, we explore the spectrum of comorbidities linked to AD.Annual Trends in Medicare Part D Prescription Claims for Guselkumab, 2018–2020
https://practicaldermatology.com/programs/practical-dermatology-focus-psoriasis/annual-trends-in-medicare-part-d-prescription-claims-for-guselkumab-20182020/28861/Jachin Wu, MD, FAAD, and colleagues talk about Medicare claims for guselkumabThe Case for JAK Inhibitors to Treat AD
https://practicaldermatology.com/topics/atopic-dermatitis/case-jak-inhibitors-treat-ad/27109/E. James Song, MD, FAAD, Director of Clinical Research and Co-Chief Medical Officer for Frontier Dermatology, discusses his presentation “JAK Inhibitors in Atopic Dermatitis” from the 2024 American Academy of Dermatology (AAD) Innovation Academy.Panic-induced Digital Marketing: Avoid Short-sighted Shifts in Long-term Strategy
https://practicaldermatology.com/topics/practice-management/panic-induced-digital-marketing-avoid-short-sighted-shifts-in-long-term-strategy/26662/Panic-induced Digital Marketing: Avoid Short-sighted Shifts in Long-term StrategyThe Future of Aesthetic Medicine in the US
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-future-of-aesthetic-medicine-in-the-us/23853/A look at five trends shaping the aesthetics market.